EOLS 📈 Evolus - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30052C1071
EOLS: Botulinum Toxin, Dermal Fillers
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California. Web URL: https://www.evolus.com
Additional Sources for EOLS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
EOLS Stock Overview
| Market Cap in USD | 702m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2018-02-08 |
EOLS Stock Ratings
| Growth 5y | 9.32% |
| Fundamental | 17.5% |
| Dividend | - |
| Rel. Strength Industry | -310 |
| Analysts | 4.43/5 |
| Fair Price Momentum | 7.45 USD |
| Fair Price DCF | - |
EOLS Dividends
No Dividends PaidEOLS Growth Ratios
| Growth Correlation 3m | -91.8% |
| Growth Correlation 12m | 2.4% |
| Growth Correlation 5y | 61.3% |
| CAGR 5y | -3.45% |
| CAGR/Mean DD 5y | -0.08 |
| Sharpe Ratio 12m | -0.03 |
| Alpha | -36.94 |
| Beta | 1.18 |
| Volatility | 55.50% |
| Current Volume | 723.6k |
| Average Volume 20d | 693.4k |
What is the price of EOLS stocks?
As of January 15, 2025, the stock is trading at USD 9.47 with a total of 723,603 shares traded.
Over the past week, the price has changed by -10.91%, over one month by -14.86%, over three months by -43.16% and over the past year by -6.04%.
As of January 15, 2025, the stock is trading at USD 9.47 with a total of 723,603 shares traded.
Over the past week, the price has changed by -10.91%, over one month by -14.86%, over three months by -43.16% and over the past year by -6.04%.
Is Evolus a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Evolus is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 17.50 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EOLS as of January 2025 is 7.45. This means that EOLS is currently overvalued and has a potential downside of -21.33%.
Neither. Based on ValueRay Fundamental Analyses, Evolus is currently (January 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 17.50 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EOLS as of January 2025 is 7.45. This means that EOLS is currently overvalued and has a potential downside of -21.33%.
Is EOLS a buy, sell or hold?
Evolus has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy EOLS.
Evolus has received a consensus analysts rating of 4.43. Therefor, it is recommend to buy EOLS.
- Strong Buy: 3
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for EOLS stock price target?
According to ValueRays Forecast Model, EOLS Evolus will be worth about 8.3 in January 2026. The stock is currently trading at 9.47. This means that the stock has a potential downside of -12.57%.
According to ValueRays Forecast Model, EOLS Evolus will be worth about 8.3 in January 2026. The stock is currently trading at 9.47. This means that the stock has a potential downside of -12.57%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 23.4 | 147.4% |
| Analysts Target Price | 20.3 | 113.8% |
| ValueRay Target Price | 8.3 | -12.6% |